Biodegradable Ophthalmic Composition for Sustained Ocular Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ocular drug administration methods for posterior segment diseases face challenges such as the tear, corneal, and blood-aqueous humor barriers, requiring multiple injections and surgeries, causing patient discomfort and increased infection risk, while existing implants are complex and costly.
Innovation Solution
An ophthalmic pharmaceutical composition in liquid form, suitable for conventional injection, comprising an active ingredient, biodegradable liquid and solid matrices, allowing slow release and degradation in the eye, eliminating the need for complex administration devices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If periocular injection administration or intravitreal injection administration is used to increase the amount of drug reaching the posterior segment, then the therapeutic effect is improved, but the frequency of multiple injections increases causing patient pain, reduced compliance, and increased risk of intraocular infection
Solution Approach 1:
The patent applies preliminary action by incorporating the drug into a biodegradable implant that is pre-prepared and designed to release the drug slowly over time. This eliminates the need for repeated injections, as the implant provides sustained therapeutic effect through controlled drug release, thereby reducing patient pain and infection risk while maintaining therapeutic efficacy
Solution Approach 2:
The patent changes the parameter of drug delivery from acute repeated injections to chronic sustained release. By using biodegradable materials with controlled degradation rates, the drug release kinetics are modified to maintain therapeutic levels over extended periods, transforming the treatment paradigm from frequent interventions to a single implantation with prolonged effect
2Duration of action of stationary object
If non-biodegradable sustained-release implants are used to reduce injection frequency, then the sustained-release effect is improved, but secondary surgery is required for removal increasing device complexity and patient burden
Solution Approach 1:
The patent applies discarding and recovering by using biodegradable materials that naturally decompose in the body after delivering the drug. The implant is designed to be discarded by the body's natural metabolic processes, eliminating the need for surgical removal. The degradation products are safely metabolized and excreted, simplifying the overall treatment process
Solution Approach 2:
The patent employs disposable biodegradable implants that are designed for single use and natural degradation. These implants are inexpensive to manufacture and eliminate the need for complex removal procedures. The biodegradable nature allows the implant to serve its purpose and then naturally disappear, reducing long-term device complexity and patient burden
3Ease of operation
If biodegradable sustained-release implants are used to avoid secondary surgery, then the ease of operation is improved, but the administration still requires specialized devices and procedures increasing device complexity
Solution Approach 1:
The patent applies universality by designing the biodegradable implant to serve multiple functions: it acts as both the delivery vehicle and the controlled-release mechanism. The implant can be administered through various routes (ocular, systemic, local) depending on the disease target, eliminating the need for specialized dedicated devices. The same implant design can be adapted for different therapeutic applications
Solution Approach 2:
The patent extracts the complex specialized injection device from the treatment system by using a simplified implant design that can be administered through conventional methods. The implant itself is designed to be self-contained, requiring no complex external delivery mechanism, thereby simplifying the overall administration process while maintaining effective drug delivery
4Reliability
If multiple injection administrations are used to maintain therapeutic drug levels, then the therapeutic effect is improved, but the loss of time and patient burden increase
Solution Approach 1:
The patent applies continuity of useful action by designing a sustained-release implant that continuously delivers the drug at controlled rates over an extended period. This eliminates the discontinuous nature of repeated injections, providing uninterrupted therapeutic effect. The implant maintains steady drug levels in the target tissue, ensuring continuous therapeutic action without requiring patient visits for additional injections
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Facilitates easy and pain-free drug delivery with sustained release, enhancing patient compliance and reducing treatment costs by using a simple injection method with ergonomic force requirements.
Implementation Method 1
can slowly release the active pharmaceutical ingredient in the eye for a long time
Implementation Method 2
can degrade in the eye
Implementation Method 3
can degrade in the eye
Implementation Method 4
can degrade in the eye
Data Source
Figure 1~2
Figure 3
AI summary
An ophthalmic pharmaceutical composition and a preparation method therefor, an ophthalmic kit containing the ophthalmic pharmaceutical composition, and a use of the ophthalmic pharmaceutical composition or the ophthalmic kit in the preparation of a drug for preventing and/or treating an eye disease. The pharmaceutical composition contains or is composed of the following components: 1 part by weight of an active pharmaceutical ingredient, 0.95-1.25 parts by weight of a liquid matrix, and 0.35-0.45 parts by weight of a solid matrix, wherein the particle size of the active pharmaceutical ingredient meets: D90≤50 µm.